EUVIMEDEUVIMED entdecken
Kohortenstudie

S100 calcium‐binding protein beta (S100B) in serum as a biomarker for epilepsy after traumatic brain injury: A register‐based cohort study in Danish adults

Kasper Lolk iD, Johan Zelano iD, Betina Bitsch Trabjerg iD, Julie Werenberg Dreier iD, Jakob Christensen iD

Epilepsia · 2026

DOI: 10.1002/epi.70049 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Epilepsia, 2026. Verfasst von Kasper Lolk und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, National Center for Register-Based Research, Aarhus University, Aarhus, Denmark. Hauptthemen laut MEDLINE: S100 Calcium Binding Protein beta Subunit, Brain Injuries, Traumatic, Epilepsy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 90 Literaturangaben. Gefördert von: Lundbeck Foundation, Novo Nordisk Fonden, Region Midtjylland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study was undertaken to evaluate whether elevated serum levels of S100 calcium‐binding protein beta (S100B) provide a prognostic biomarker for the development of epilepsy after traumatic brain injury (TBI).

Methods

We conducted a register‐based cohort study in adults (≥18 years of age) who presented to Danish emergency departments between 2013 and 2022 with a head injury and underwent serum S100B sampling. We classified injury severity hierarchically according to TBI diagnoses (No TBI, mild TBI without [mTBI−] and with [mTBI+] detectable lesions) recorded the first week after injury admission. Epilepsy onset was set to the date of the first epilepsy diagnosis or first redeemed antiseizure medication prescription after TBI. Persons were followed until epilepsy onset, death, or December 31, 2022, whichever came first. We estimated hazard ratios (HRs) and absolute risk (AR) of epilepsy according to S100B levels with corresponding 95% confidence intervals (CIs), according to injury severity, age, sex, and multimorbidity.

Results

Mean serum S100B levels increased with TBI severity ( p < .0001). A 1‐unit S100B increase (in μg/L) after TBI carried increased epilepsy risk (HR = 1.46, 95% CI = 1.20–1.77), but only in mTBI+ patients (HR = 2.12, 95% CI = 1.55–2.92). The overall 5‐year AR of epilepsy after any head injury was 3.8% (95% CI = 1.5%–7.8%), 2.0% (95% CI = 1.2%–3.1%), and 1.0% (95% CI = .8%–1.3%) in patients with S100B levels of 2.0, 1.0, and .1 μg/L, respectively, and in the subgroup of mTBI+ patients the ARs were 21.3% (95% CI = 9.0%–38.2%), 5.7% (95% CI = 2.6%–10.6%), and .8% (95% CI = .2%–2.4%). Age and sex had minor influence on the association, but having a high multimorbidity score (HR = 2.03, 95% CI = 1.28–3.23) was a pivotal modifier, rendering the association insignificant in those without (HR = 1.21, 95% CI = 0.88–1.67). Significance Elevated serum S100B levels after TBI were associated with subsequent epilepsy, likely reflecting the extent of intracranial injury. Despite study limitations, these findings support the potential of S100B as a prognostic biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

S100 Calcium Binding Protein beta SubunitBrain Injuries, TraumaticEpilepsyHumansMaleFemaleAdultBiomarkersMiddle AgedDenmarkCohort StudiesRegistriesAgedYoung AdultAdolescent

Stichwörter der Autor:innen

S100BTBIepidemiologyobservational studyposttraumatic epilepsy

Substanzen

S100 Calcium Binding Protein beta SubunitBiomarkersS100B protein, human

Autor:innen und Institutionen

  • Department of Public Health, National Center for Register-Based Research, Aarhus University, Aarhus, Denmark.
  • Center for Integrated Register-Based Research, Aarhus University, Aarhus, Denmark.
  • Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Wallenberg Center of Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
  • Department of Neurology, Sahlgrenska University Hospital, member of European Reference Network EpiCARE, Gothenburg, Sweden.
  • Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.

ORCID-Profile: Kasper Lolk, Johan Zelano, Betina Bitsch Trabjerg, Julie Werenberg Dreier, Jakob Christensen

Förderung

  • Lundbeck Foundation
  • Novo Nordisk Fonden
  • Region Midtjylland
  • Epilepsiforeningen

Zitieren

APA

Lolk, K., Zelano, J., Trabjerg, B. B., Dreier, J. W., & Christensen, J. (2026). S100 calcium‐binding protein beta (S100B) in serum as a biomarker for epilepsy after traumatic brain injury: A register‐based cohort study in Danish adults. Epilepsia. https://doi.org/10.1002/epi.70049

Vancouver

Lolk K, Zelano J, Trabjerg BB, Dreier JW, Christensen J. S100 calcium‐binding protein beta (S100B) in serum as a biomarker for epilepsy after traumatic brain injury: A register‐based cohort study in Danish adults. Epilepsia. 2026. doi:10.1002/epi.70049

BibTeX
@article{Lolk2026,
  author = {Lolk, Kasper and Zelano, Johan and Trabjerg, Betina Bitsch and Dreier, Julie Werenberg and Christensen, Jakob},
  title = {S100 calcium‐binding protein beta (S100B) in serum as a biomarker for epilepsy after traumatic brain injury: A register‐based cohort study in Danish adults},
  journal = {Epilepsia},
  year = {2026},
  doi = {10.1002/epi.70049}
}
Kostenlos starten →